Member Info for avctIPmatters

Avacta open for business deals :

[LINK REMOVED]

"

Partnering for success

Partnering is key to Avacta’s strategy as we continue to expand our pipeline of innovative treatments for cancer.

Our partnering strategy includes teaming up with pharmaceutical partners to help advance our pipeline products through to market, as well as combining our proprietary platforms with novel warheads to develop next generation cancer therapies.

Contact us

To explore how we can work together, please contact our Chief Business Officer simon.bennett@avacta.com"

Still no mention of replacing CSO/CMO/CDO kind of suggests AVA6000 for selected cancer indications will be done with JV partners ,but retain IP etc. Speed up the process & generate Royalties and licence fees.

[LINK REMOVED]

Professor Udai Banerji - Guess must be pleased with trial progress always best to listen to the experts .

" Other areas of interest include finding new drug targets and designing novel anticancer agents, study of tumour stroma in drug development including cancer associated fibroblasts and herding of cancer evolution."

Might take a while longer but true value of Avacta Therapeutics assets/IP still to be recognised IMO .

----------

Biosketch

Professor Udai Banerji is the co-director of the Drug Development Unit at The Institute of Cancer Research

and the Royal Marsden NHS Foundation Trust. The unit is internationally recognized for its expertise

in running first in human clinical trails of anticancer drugs and associated translational research.

His clinical interests include finding optimal dose and schedules of novel anticancer drugs using preclinical

and clinical pharmacokinetic and pharmacodynamic data along with toxicity. Another area of interest is

designing and running clinical trials of combination therapy that is a clinical translation of his preclinical

laboratory programs.

Professor Banerji’s runs two laboratories. The first is the Clinical Pharmacodynamics Biomarker Labs

which sets and runs bespoke pharmacodynamic assays to be used in tumour biopsies and surrogate

normal tissue in samples taken during phase I trials.

The second laboratory, the Clinical Pharmacology Adaptive Therapy group studies drug resistance and methods to overcoming this using combination therapy. He profiles dynamic phosphoproteimic changes and in collaborations with bioinformaticians creates executable models to predict combinations to overcome drug resistance. Other areas of interest include finding new drug targets and designing novel anticancer agents, study of tumour stroma in drug development including cancer associated fibroblasts and herding of cancer evolution."

Staff keeping their spirits up ; ( must be a concern "LD up for sale " )

---------------------------

"Launch Diagnostics LimitedLaunch Diagnostics Limited

1,924 followers1,924 followers

1h • 1 hour ago

The team at Launch Diagnostics are currently participating in a virtual exercise challenge to cover the distance from Lands End to John O’Groats.

The challenge has fostered teamwork, encouraged physical activity, and boosted the teams’ mental wellbeing. Through working towards a shared goal, our team stay connected, energised, and engaged, enhancing productivity and creating a positive work environment, even remotely.

Congratulations to our team for completing 40% of our goal so far! Trees are planted for each milestone within the challenge, creating a sense of shared accomplishment, with benefits for environmental sustainability.

hashtag#endtoend hashtag#launchdiagnostics hashtag#wellbeing hashtag#sustainability

Sorry links not working anyway perhaps just info from yesterday presentation updated .

[LINK REMOVED]

Sorry gmcc deleted had to delete my account as personal details email disclosed silly me . Anyway back today .

FYI

[LINK REMOVED] 0 2024-10-01 08:41 +00:00

[LINK REMOVED] 0 2024-10-01 08:45 +00:00

[LINK REMOVED] 0 2024-10-01 08:47 +00:00

[LINK REMOVED] 0 2024-10-01 08:49 +00:00

[LINK REMOVED] 0 2024-10-01 08:52 +00:00

[LINK REMOVED] 0 2024-10-01 08:50 +00:00

[LINK REMOVED] 0 2024-10-01 08:50 +00:00